Methods: Part 1 -Rats were treated with NMS (5 mg/kg), DXM (1 mg/kg), PTF (10 mg/kg) and MTK (20 mg/kg) for 2 weeks through a daily intraperitoneal injection. At the end of drug treatment animals were subjected to an amphetamine (0.5 mg/kg)-induced hyperactivity test in which total distance travelled, mean velocity and the time spent in the center of an open field arena were measured. Part 2 -Rats were subjected to an aggression-inducing protocol (the resident-intruder aggression test, RIAT) for 4 weeks, at the last 2 weeks of which they were treated with NMS, DXM, PTF and MTK as described above. Then, aggressive behavior was evaluated by counting the number of attacks by "resident" (aggressive) rats against "intruder" (subject to aggression) rats. Results and Discussion: Part 1-The administration of amphetamine prominently increased total distance travelled, mean velocity and time spent in center of the arena. NMS significantly and PTF non-significantly decreased all 3 tested measures. In contrast, DXM and MTK did not significantly alter the 3 tested measures (MTK increased time spent at center). Part 2 -PTF significantly attenuated aggressive behavior (number of attacks) among resident rats, while NMS, DXM and MTK did not have a significant effect. These results suggest that anti-inflammatory drugs do not exhibit potent anti-manic-like effects. Abstract Abnormalities in the glucose metabolism could be a main cause for the increased morbidity and mortality rates found in patients with bipolar disorders. However, the exact prevalence of diabetes and pre-diabetic abnormalities is not clear. We conducted a prospective cohort study for metabolic measures during antipsychotic treatments in patients with schizophrenia and bipolar disorder (matSaB study) using the Japanese blood glucose monitoring guidance (Kusumi et al. 2011) in order to find undiagnosed hyperglycemia systematically as a routine clinical practice. In this study, we aimed to report a cross-sectional analysis of baseline data to quantify the frequency of glucose abnormalities in patients with bipolar disorder.
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Effect of Quetiapine XR on Circadian Rhythm Compared with Lithium in Patients with Bipolar Depression
Department of Psychiatry and Center for Sleep and Chronobiology, Seoul National University College of Medicine and Hospital
Abstract Introduction: Bipolar disorder commonly has chronobiological disruption and its therapeutic medicines, like lithium has a phase delay effect. In the current study, we compared the effect of quetiapine XR and lithium on circadian rhythm in bipolar depression patients during 8 weeks of trial.
Methods: An open-label, randomized comparison of sleepactivity and depressive symptoms between 8-week quetiapine XR monotherapy and lithium monotherapy for bipolar depression was conducted. Each assessment consisted of Hamilton Depression Rating Scale (HDRS)-17 and self-reported Pittsburgh Sleep Quality Index (PSQI). Actigraphy-measured sleep parameters were assessed and the circadian rhythm were examined using cosinor analysis. Results: A total of 28 patients(35.9 ± 10.5 years; gender:male12, female16) with bipolar depression were analyzed. Lithium group are 16 patients and quetiapine XR group are 12 patients, there are no significant deference in age and gender. To examine the circadian rhythms, we compared the acrophase in each group. Acrophase of lithium group significantly delayed at weeks1, 2, 4, 6 and 8 compared with baseline (16:22 ± 1:14, 17:20 ± 0:29, 17:33 ± 0:39, 18:27 ± 0:45, 18:42 ± 0:30, 19:04 ± 0:28, p=0.008). Acrophase of quetiapine XR group were advanced than those of lithium group at every weeks (p=0.001), and did not delay in sequence (13:50 ± 0:46, 15:54 ± 0:24, 14:05 ± 1:28, 16:12 ± 0:36, 16:23 ± 0:27, 15:38 ± 0:24) In both groups, HDRS-17 scores were significantly decreased at weeks1, 2, 4, 6 and 8 compared with baseline. In the quetiapine XR group, PSQI scores at weeks1, 2, 4, 6 and 8 was significantly decreased compared with baseline and sleep efficiency (SE) at week 6 and 8 was significantly increased. Conclusion: Both quetiapine XR and lithium was effective in treating bipolar depression. But lithium was also delay phase, as well as not have to improve the quality of sleep. On the contrary quetiapine XR treatment improved subjective and objective sleep quality in patients with bipolar depression. And quetiapine XR treatment did not affect circadian rhythm.
PS36
Screening for diabetes using Japanese blood glucose monitoring guidance in patients with bipolar disorder treated with antipsychotics: A cross-sectional analysis of baseline data Abstract Abnormalities in the glucose metabolism could be a main cause for the increased morbidity and mortality rates found in patients with bipolar disorders. However, the exact prevalence of diabetes and pre-diabetic abnormalities is not clear. We conducted a prospective cohort study for metabolic measures during antipsychotic treatments in patients with schizophrenia and bipolar disorder (matSaB study) using the Japanese blood glucose monitoring guidance (Kusumi et al. 2011 ) in order to find undiagnosed hyperglycemia systematically as a routine clinical practice. In this study, we aimed to report a cross-sectional analysis of baseline data to quantify the frequency of glucose abnormalities in patients with bipolar disorder.
A total of 171 patients with bipolar disorder, who had not been diagnosed as diabetes prior to baseline screening and started one-year monitoring between April 2013 and March 2015, were enrolled at 45 sites in Japan. Participants included both in-and outpatients who started some new antipsychotics at baseline monitoring. The study protocol was approved by the institutional review board of each site. All participants provided written informed consent after receiving a full explanation of the study protocol. This study was supported by grants from the Earlyphase/Exploratory or International-standard Clinical Research by Japan Agency for Medical Research and Development.
Out of 171 patients, 10 (5.8%) met criteria for probable diabetic type, 20 (11.7%) for pre-diabetic type, and 141 (82.5%) for normal type. Individuals with pre-diabetic and probable diabetic type showed a significantly higher serum triglyceride than those with normal type. There was no significant difference in body mass index, total or HDL-cholesterol, or the frequency of family history of diabetes among the three types.
One-year follow-up study is underway to assess the detective power and usefulness of the blood glucose monitoring guidance for patients with bipolar disorder. 
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